Angelini Pharma buys Catalyst for $4.1B
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Angelini Pharma announced a cash acquisition of Catalyst Pharmaceuticals for roughly $4.1 billion.
- Catalyst Pharmaceuticals is valued at $31.50 per share, a 28% premium to its price in the 30 days before April 22.
- Angelini Pharma will gain a foothold in the U.S. market and strengthen its neurology portfolio through the purchase.
- Catalyst currently markets three approved rare‑disease medicines that will become part of Angelini’s lineup.
Why it matters: Angelini gains U.S. market access and a neurology boost; Catalyst shareholders receive $31.50 per share cash premium. The deal expands Angelini’s rare‑disease pipeline, increasing its revenue share in a high‑growth segment.
